Pharm-to-Trial Expansion RxE2 is launching a Pharm-to-Trial model leveraging local pharmacies as regional hubs, presenting a direct sales opportunity to pharmaceutical sponsors seeking decentralized trial capabilities and improved patient recruitment and retention through community pharmacists.

Tech-Driven Platform The company emphasizes AI and ML powered trial management and a proprietary technology platform, suggesting upsell potential to sponsors and CROs looking to enhance data analytics, patient engagement, and trial logistics with advanced software.

Network Synergy With a vast network of community pharmacists and a growing nurse network through partnerships like Hawthorne Health, RxE2 can be pitched as a scalable, multi-site site-access strategy to diversify patient populations and accelerate enrollment.

Recognition & Growth repeated recognitions as a top tech startup in North Dakota and active conference participation indicate momentum and credibility, which can be leveraged in co-marketing, case studies, and credibility-building outreach to potential customers.

Financial Profile Revenue in the lower-mid tens of millions with modest funding positions RxE2 as a lean, growth-ready partner for sponsors seeking innovative, cost-efficient trial solutions rather than large incumbent deployments.